Meeting Banner
Abstract #3910

Brain lithium and myo-inositol levels in lithium treated and non-lithium treated bipolar disorder patients

Fiona Elizabeth Smith1, Peter Edward Thelwall1, Carly Jay Flowers2, Matthew George Birkbeck1, Joe Necus2, Andrew Matthew Blamire1, and David Andrew Cousins2

1Institute of Cellular Medicine, Magnetic Resonance Centre, Newcastle University, Newcastle upon Tyne, United Kingdom, 2Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, United Kingdom

The action of lithium in bipolar disorder (BD) is incompletely defined but the inositol depletion hypothesis1 states that lithium inhibits IMPase to deplete myo-inositol, confirmed in vivo using proton magnetic resonance spectroscopy (1H-MRS) following acute treatment2,3 Chronic treatment may upregulate IMPase, with trend-level increases in grey matter myo-inositol reported.4 This 1H-MRS study compares frontal white matter myo-inositol/creatine levels (8cm3 voxel) in BD subjects (lithium-treated versus BD controls taking other medication), supplemented by measuring brain lithium signal intensity using 3D 7Li-MRI. Myo-Ino/Cr levels were significantly lower in the lithium-treated group, but their levels did not correlate with 7Li-MRI signal intensity.

This abstract and the presentation materials are available to members only; a login is required.

Join Here